The U.S. Senate held its first hearing on the menopause care gap. Read what proposed federal research and new legislation could mean for midlife women.
On September 16, 2026, the U.S. Senate Special Committee on Aging held what lawmakers described as Congress’s first hearing devoted exclusively to menopause. The bipartisan event convened under the title “Half the Country, Zero Hearings” to address persistent shortfalls in clinical research, medical education and patient care.
Medical consensus has historically sidelined the physical shifts of midlife. This approach left patients to navigate a highly fragmented medical system with little support. The previous standard of care often offered limited choices, leaving clinicians without the rigorous scientific data needed to build comprehensive treatment plans. Obstetrics and gynecology education focused largely on reproductive issues and pregnancy, creating a substantial gap in post-reproductive health training.
Dr. Suzanne Silverman Fenske stated that her own core medical education included little specific menopause training. This educational blind spot means many highly qualified specialists simply lack the foundation to evaluate shifting body composition or sleep disruptions. Patients expect evidence-based guidance, but their primary care providers often lack the clinical preparation to discuss hormone variability with confidence.
Federal research priorities reflect this historical lack of attention. Witnesses at the hearing explained that midlife women's health receives far less funding than its broad impact would suggest. Jennifer Weiss-Wolf told the committee that less than 1 percent of federal research funding goes to menopause and midlife women’s health. Without sustained investment, medical professionals have fewer proven therapies to offer their patients.
The consequences of this care gap affect more than 1 million U.S. women who reach menopause each year. This statistic comes from broadcast coverage of the recent hearing. Women routinely face compounding challenges, from limited insurance coverage to medication shortages. Finding accurate perimenopause and menopause information often requires overcoming significant geographic and financial barriers.
The Senate hearing coincided with a bipartisan push to modernize midlife health policy. Senators Patty Murray and Lisa Murkowski reintroduced the Advancing Menopause Care and Mid-Life Women’s Health Act. This legislation aims to build clear clinical frameworks and fund new scientific studies. The proposed bill outlines several significant updates to how the federal government handles female health research.
The proposed legislative updates and structural improvements include:
The September 16 hearing stood out for its collaborative political approach to female health. Committee Chair Rick Scott, a Republican from Florida, and Ranking Member Kirsten Gillibrand, a Democrat from New York, both participated actively in the discussion. The event was presented strictly as a policy discussion rather than an attempt to promote any single commercial treatment approach.
Gillibrand noted that menopause affects more than 75 million U.S. women. She argued that the historical absence of a dedicated congressional hearing was unacceptable for such a widespread health transition. Her remarks framed the care gap not just as a medical oversight, but as a systemic failure to support a massive segment of the adult population.
Scott reinforced this perspective by focusing on informed choice and practical access. He stated that women should have good information, an appropriate health-care provider and multiple treatment options. This bipartisan framing is necessary for advancing legislation in a divided political environment.
Treating menopause as a universal health priority allows lawmakers to focus on clinical outcomes rather than partisan talking points. The shared recognition of the care gap marks a significant departure from previous congressional sessions. This unified front gives the proposed legislation a much more realistic path forward.
Hearing participants repeatedly noted that federal investment could solve multiple structural problems at once. Experts stated that funding could help train clinicians, study hormonal therapies and investigate possible links between menopause and cognitive function. This comprehensive approach treats midlife health as a multifaceted medical discipline.
The Aging Committee lacks the authority to legislate directly, meaning the hearing itself does not immediately create new funding. To maintain momentum, Scott and Gillibrand requested a formal Government Accountability Office review. This bipartisan request asks the GAO to examine how federal agencies currently fund and coordinate menopause research.
Scott clarified that the policy objective is not finding a single universal therapy for every patient. The focus remains on making certain women have access to reliable information and appropriate healthcare providers. Medical professionals point out that effective care requires an individualized approach rather than rigid protocols. Clinical care may involve hormonal therapies, nonhormonal options, symptom-specific treatments and the evaluation of coexisting conditions.
This individualized focus protects patients from being pushed toward a single treatment pathway. Menopause symptoms can be genuinely disruptive, but not every physical shift automatically requires a hormonal explanation. The hearing coverage highlighted better evaluation and access to care, giving clinicians the flexibility to address distinct physical changes.
The proposed legislation could also reduce the burden on patients who currently piece together their own care teams. A more coordinated federal research strategy would help primary care providers stay updated on the latest treatment guidelines. This structural support is necessary for building a healthcare system that proactively addresses midlife changes.
Congressional scrutiny of midlife health aligns with renewed regulatory attention to specific hormone therapies. U.S. health regulators convened a public review of testosterone’s potential benefits, risks and role in female health on September 17, 2026. This separate regulatory evaluation highlights the growing demand for comprehensive discussions about female hormone use.
There is currently no FDA-approved testosterone therapy specifically for women. Reuters reported that clinicians have used testosterone off-label for some menopausal women with hypoactive sexual desire disorder. Regulators are now evaluating the dosing, long-term safety and overall clinical evidence for this specific application.
Experts at the testosterone review presented differing views on the breadth of the current clinical data. Some professionals called for a female-specific product to standardize dosing and improve safety for patients. Others pointed out significant evidence gaps and urged caution until more rigorous long-term safety studies are finalized.
This ongoing regulatory debate illustrates why expanded NIH research funding is necessary. Understanding the risks and benefits of various therapies requires concrete data rather than medical assumptions. Addressing concerns about desire, comfort and intimate confidence depends entirely on high-quality medical research.
While federal policy slowly advances, women still need practical strategies for managing their health right now. The Senate hearing represents a political milestone rather than an immediate clinical recommendation. Patients should not assume that the proposed Centers of Excellence are currently operating or that the bill has passed. Comprehensive midlife care still requires proactive patient communication and careful clinical evaluation today.
The hearing underscored the critical need for access to knowledgeable clinicians. If physical shifts are affecting sleep, mood, energy or daily functioning, patients can ask their provider to evaluate both hormonal and nonhormonal options. Bringing specific questions helps clinicians focus on the most relevant physical shifts without resorting to a rushed prescription.
A productive clinical appointment involves discussing symptom timelines, menstrual changes and comprehensive medical history. Patients should also raise sleep concerns, medication interactions and cardiovascular or bone-health considerations. This careful preparation helps ground the appointment in factual physical data rather than vague complaints. This organized approach makes managing strength, body composition and metabolism much more straightforward.
The push for informed choice means patients must actively evaluate any proposed treatments. When a clinician recommends a specific intervention, women should ask what the current evidence actually supports. Understanding what is known and what remains uncertain helps patients make clear-headed decisions about their own bodies.
Patients should ask about potential alternatives and how follow-up care will be handled. This critical evaluation is particularly relevant for off-label treatments where medical experts continue to debate the limits of available evidence. Asking for clear clinical proof prevents patients from accepting generic advice that ignores their individual health history.
Preparing for these appointments also involves setting realistic expectations about treatment timelines. Finding the right management strategy often requires careful adjustments and regular follow-up visits. Clear communication with a provider makes this ongoing process much less frustrating.
Women in rural or underserved areas face additional logistical barriers when seeking appropriate care. Witnesses at the hearing identified rural clinician shortages as a significant obstacle to quality medical attention. Patients in these regions might need to request telehealth options or seek referral networks to reach professionals with additional menopause training.
The congressional hearing signals a shift in how national institutions view midlife women's health. For decades, the medical system treated menopause as a private burden rather than a public health priority. Acknowledging this gap at the federal level helps validate the daily experiences of millions of midlife women.
Policy momentum takes time to translate into systemic reform. Authorizing funds through the proposed act is distinct from actually appropriating those dollars for immediate use. Developing new training curriculums for medical students will take years to alter standard clinical practice.
Until educational standards improve across the board, women must advocate for their own evidence-based care. The bipartisan support for the Advancing Menopause Care and Mid-Life Women’s Health Act shows that lawmakers recognize the structural problem. Federal agencies must now take practical steps to coordinate research and improve public health information.
Treating midlife women as capable adults requires moving beyond isolated symptom management and recognizing the broader physical transition. Finding a provider who relies on credible research is the first step toward better daily care.
As federal scrutiny drives better clinician training and research coordination, midlife women will eventually see more individualized treatment options rather than relying on historical trial and error.
While the federal push for better medical training highlights the current lack of structured clinical guidance, navigating these physiological shifts remains a daily reality for midlife women. Refemina translates the emerging clinical evidence, helping you manage changes in strength, muscle, body composition, metabolism or weight without relying on wellness hype.
Follow Refemina for research-led insights on menopause, strength, metabolism, nutrition, skin, intimacy and confidence through midlife. New articles turn complex topics into clear, useful context.
Keep learning about the changes that shape energy, strength, confidence and wellbeing through midlife.
Explore Resources